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The epigenetic regulation of cancer cells by small non-coding RNA molecules, the microRNAs (miRNAs),
has raised particular interest in the ﬁeld of oncology. These miRNAs play crucial roles concerning
pathogenic properties of cancer cells and the sensitivity of cancer cells towards anticancer drugs. Certain
miRNAs are responsible for an enhanced activity of drugs, while others lead to the formation of tumor
resistance. In addition, miRNAs regulate survival and proliferation of cancer cells, in particular of cancer
stem-like cells (CSCs), that are especially drug-resistant and, thus, cause tumor relapse in many cases.
Various small molecule compounds were discovered that target miRNAs that are known to modulate
tumor aggressiveness and drug resistance. This review comprises the effects of naturally occurring small
molecules (phenolic compounds and terpenoids) on miRNAs involved in cancer diseases.
© 2016 The Author. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
The investigation of the role of microRNAs (miRNAs), short and
highly conserved non-coding RNAs of 22-23 nucleotides, for
various diseases has risen distinctly over the last years. At the
moment, there are more than two thousand miRNAs that regulate
about one-third of all human genes [1]. MiRNAs are involved in the
regulation of processes such as proliferation, apoptosis, and dif-
ferentiation of cells [2]. Concerning cancer, miRNAs can exert either
tumor suppressor or oncogenic activities [1]. Characteristic pat-
terns of miRNA expression were observed from certain tumor tis-
sues and, thus, miRNAs can also feature valuable diagnostic and
prognostic factors [3e7]. In addition, miRNAs play a crucial role for
the formation and survival of cancer stem-like cells (CSCs) [8,9].
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mation of metastases [10,11].
Mature miRNAs bind to target messenger RNAs (mRNAs) and
suppress their translation [12]. The biosynthesis of miRNAs
generally starts with the transcription of miRNA genes by RNA
polymerase II thus generating precursor miRNAs (pri-mRNAs) of
several kilobases [13]. Then, the microprocessor complex including
the RNase III enzyme Drosha and DGCR8 processes these pri-
mRNAs into pre-mRNAs of 65-70 nucleotides that form hairpin
structures in the nucleus [13,14]. These pre-miRNAs are transported
from the nucleus to the cytoplasm via the transporter Exportin-5 in
a Ran-GTPase dependent way [15e17]. In the cytoplasm, the pre-
miRNAs are processed by the Dicer-TRBP (tar binding protein)
complex leading to double-stranded RNAs which comprise the
mature miRNA and its complementary strand [1,15e17]. After
separation from the complementary strand, the mature miRNA
binds to the AGO2 (Argonaut 2) protein which recruits further
proteins forming miRISC (miRNA-induced silencing complex) [18].
MiRISC is able to bind to target mRNAs leading either to a block of
translation or to the degradation of the target mRNAs by miRISC.
The seed region of the miRNA (nucleotides 2-7 of the 50-end of the
miRNA) binds to the complementary 30-untranslated regions (UTR)
of targetmRNAs leading to inhibition of mRNA translation [9,19,20].
Aside negative regulation of mRNA translation, certain miRNAs
were also found to promote mRNA translation by recruitment ofAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND
terpenoidal dietary factors and natural products as non-coding RNA/
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translation inhibiting proteins [21,22].
It was observed that singlemiRNAs can target various geneswhile
dysregulation of tumor suppressor or oncogenic miRNAs can be
found in many human cancer types [23,24]. Thus, miRNAs with ef-
fects on carcinogenesis, cell proliferation and differentiation,
apoptosis, and on the formation of metastasis and drug resistance
feature a valuable target for the design of potent anticancer drugs
[25e27]. The application of accurate miRNAs (either as mimics or as
antagomirs) in therapy is limited due to the lowcell permeability and
the facile degradation of RNA molecules, however, liposomal for-
mulations such as MRX34 of the tumor suppressor miRNA-34a
(Mirnarx Therapeutics) revealed sufﬁcient stability and cell delivery
of the anti-cancer active miRNA leading to the initiation of phase I
clinical trials with MRX34 [18]. Nevertheless, dietary factors and
natural products are easily obtained from natural sources and, thus,
usually provide a rich supply of low-cost, safe and easily available
miRNA-modulatory drug candidates. Suitable anticancer drugs from
this pool of anticancer active dietary factors and natural products
should either inhibit the activity of oncogenicmiRNAsorpromote the
activity of tumor suppressor miRNAs. This review provides an over-
view of anticancer active natural products (phenols, terpenes) and
their manifold interactions withmiRNAs involved in cancer diseases.
2. Classiﬁcation of miRNAs as tumor suppressors or
oncogenes
2.1. Tumor suppressing miRNAs
Let-7 features one of the most prominent tumor suppressing
miRNA families, and let-7 miRNAs are distinctly downregulated or
even completely lost in certain cancer types [28]. A connection
between let-7 and K-Ras mutationwas observed and restored let-7
led to signiﬁcant tumor growth inhibition in K-Ras lung cancer
models [29,30]. Downregulation of let-7 was shown for breast,
colon, lung and pancreas carcinomas and correlated with worse
prognosis in lung cancer patients [28,29,31,32]. The ﬁrst identiﬁed
tumor suppressing microRNAs were miR-15 and miR-16 in CLL
(chronic lymphocytic leukemia) cells [33]. Increased levels of miR-
15a and miR-16-1 induced apoptosis while high levels of the anti-
apoptotic Bcl-2 protein led to reduced concentrations of miR-15a
and miR-16-1 [34]. Restored miR-16 exhibited growth inhibition
in prostate cancer cells [35]. In addition, miR-15 and miR-16
sensitized multidrug-resistant gastric cancer cells to chemo-
therapy [36]. MiR-34 is another important tumor suppressor that
attacks tumor-initiating pancreas cancer cells and leads to
apoptosis, cell-cycle arrest, and anti-angiogenesis [37e39]. Singh
and coworkers disclosed the tumor suppressing effects of miR-150
in pancreas cancer cells via repression of the oncoprotein MUC4
[40]. In mixed lineage leukemia cells (MLL) miR-495 was sup-
pressed and restoration of this miRNA led to inhibition of leukemia
cell growth both in vitro and in vivo [41]. Further examples of tumor
suppressor miRNAs with effects on hepatoma and pancreas cancer
feature miR-203 and miR-451 [42e45]. Further to this, there are
several miRNAs which explicitly suppress metastasis formation. In
breast cancer models, the expression of miRNAs such as miR-126,
miR-206, and miR-335 reduced bone and lung metastasis forma-
tion [46]. MiR-126 also inhibited the migration and invasion of
prostate cancer cells [47]. In lung cancer, miR-126 and miR-183
likewise blocked metastasis formation [48,49].
2.2. Oncogenic miRNAs
Several oncogenic miRNAs (OncomiRs) were identiﬁed which
are overexpressed in many cancer types due to gene ampliﬁcationPlease cite this article in press as: B. Biersack, Current state of phenolic and
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block tumor suppressor gene expression or regulate epigenetically
the expression of pathogenic genes (oncogenes) [51]. MiR-21 fea-
tures a prominent example of an oncogenic miRNAwhich inhibited
apoptosis in glioblastoma cells [52]. A connection with the anti-
apoptotic Bcl-2 protein was observed in breast cancer cells and
down-regulation of Bcl-2 occurred after suppression of miR-21
[53]. In pancreas cancer cells, oncogenic miR-27a was overex-
pressed and targeted the tumor suppressor Sprouty2 [54]. High
levels of miR-424-5p in pancreas cancer cells blocked apoptosis and
increased cell proliferation via SOCS6 suppression [55]. Another
important OncomiR is miR-155 that promoted the proliferation of
triple-negative breast cancers and represents a marker of bad
prognosis for pancreas cancer patients [56,57]. Various cancers
revealed an overexpression of oncogenic miR-155 [57e59]. The
miR-17-92 cluster plays an oncogenic role in various tumor diseases
and upregulation of the miR-17-92 cluster correlated with
increased tumor formation and angiogenesis [60e62]. B-cell lym-
phoma models exhibited stronger c-myc-dependent tumor growth
upon expression of the miR-17-92 cluster [63]. The miRNAmiR-10b
was upregulated in breast cancer cells and increased migration,
invasion and metastasis formation of breast cancer cells [64]. In
addition, miR-10bwas a marker for bad prognosis in primary breast
carcinoma [64]. The miRNAs miR-373 and miR-520c enhanced the
migration and invasion of cancer cells by affection of CD44
expression [65]. The metastatic potential of prostate cancer cells
was likewise increased by miR-373 and miR-520c [66]. Breast
cancer cells were able to form metastases in mice because of miR-
373 andmiR-520c overexpression [65]. In addition, clinical samples
of breast cancer metastases revealed high miR-373 levels [65].
Various miRNAs contribute to drug resistance in cancer cells.
Overexpression of miR-221 and miR-222 led to tamoxifen resis-
tance in breast cancer cells and to TRAIL (tumor necrotic factor-
related apoptosis-inducing ligand) resistance in non-small cell
lung cancer cells (NSCLC) [67,68]. The cisplatin resistance of ovarian
cancer cells correlated with increased miR-214 levels targeting
PTEN [69]. The effects of dietary and natural phenolic compounds
and terpenoids on these miRNAs as well as on further speciﬁc
miRNA examples are discussed in the following chapter. A short list
of microRNAs with signiﬁcant oncogenic or tumor suppressing
activities in the four main solid tumor diseases of Western peoples
[i.e., lung cancer, colorectal cancer, prostate cancer (men), and
breast cancer (women)] is given in Table 1 [70e73].
3. Dietary compounds and natural products (phenols and
terpenoids) with effects on miRNA expression and activity
3.1. Phenolic compounds
3.1.1. Curcumin and curcuminoids
Curcumin is a phytochemical compound isolated from the rhi-
zomes of turmeric (Curcuma longa, haldi) [74]. Turmeric has been
applied as a spice for Asian dishes and as a drug in traditional In-
dian (Ayurveda) and Chinese (TCM) medicine for centuries. Struc-
turally, curcumin is an a,b-unsaturated b-diketone
(diferuloylmethane) that shows keto-enol-tautomerism (Fig. 1)
[74]. Curcumin has been thoroughly investigated as an anti-
inﬂammatory and anticancer agent and has already undergone
several clinical trials [75]. Curcumin features a pleiotropic agent
and targets NF-kB (nuclear factor-kB), Akt (protein kinase B)
signaling, Wnt signaling, STAT-3 (signal transducers and activators
of transcription-3), COX-2 (cyclooxygenase 2), proteasome, MMP
(matrix metalloproteinase), etc. [74]. It also exhibited various ef-
fects on miRNAs, which contribute to its sound anticancer activity
[75]. In MCF-7 breast cancer cells, curcumin induced the expressionterpenoidal dietary factors and natural products as non-coding RNA/
on, Non-coding RNA Research (2016), http://dx.doi.org/10.1016/
Table 1
A selection of important microRNAs as tumor suppressors or oncogenes in breast cancer, prostate cancer, colorectal cancer and lung cancer diseases.
Compound Tumor suppressors Oncogenes
Breast cancer miR-31, miR-125b, miR-126, miR-146b, miR-200, miR-205, miR-206, miR-335 miR-10b, miR-21, miR-155, miR-373, miR-520c
Prostate cancer let-7c, miR-15, miR-16, miR-29b, miR-125b, miR-126, miR-143, miR-145,
miR-205, miR-331-3p
miR-20a, miR-21, miR-27a, miR-107, miR-141, miR-221, miR-375
Colorectal cancer miR-1, miR-17-5p, miR-29a, miR-106a, miR-125b, miR-133b, miR-143,
miR-144, miR-145, miR-150, miR-195, miR-203, miR-206, miR-345, mir-365,
miR-378
miR-9, miR-10b, miR-21, miR-31, miR-92a, miR-124, miR-135a/b,
miR-139-5p, miR-141, miR-155, miR-181a, miR-183, miR-185,
miR-200c, miR-215, miR-219-1, miR-335, miR-372, miR-608
Lung cancer let-7 family, miR-7, miR-126, miR-145, miR-183 miR-17-92 cluster, miR-31, miR-146b, miR-155, miR-221, miR-222,
miR-630
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Fig. 1. Chemical structures of curcumin, of the curcuminoids CDF and EF24 and of
garcinol.
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pressed the anti-apoptotic Bcl-2 protein [76]. These miRNAs were
also upregulated in K-562 and HL-60 leukemia cells upon treat-
ment with curcumin andWT1 (Wilm's Tumor 1) was identiﬁed as a
target of miR-15a and miR-16 here [77]. Curcumin also activated
the promoter of the miR-203 tumor suppressor gene (by hypo-
methylation) leading to the overexpression of miR-203 and
curcumin-treated bladder cancer cells showed reduced levels of
miR-203 targets, the protein kinases Akt and Src, as well as
increased apoptosis and decreased proliferation and invasion [78].
Curcumin enhanced the expression of miR-22 in Y79 retinoblas-
toma cells leading to increased cell growth andmigration inhibition
via the miR-22 target Erbb3 [79]. In triple-negative breast cancer
cells (MDA-MB-231), curcumin induced overexpression of miR-
181b leading to inhibition of the formation of MMPs (matrix met-
alloproteinases) and downregulation of the chemokines CXCL1 and
CXCL2 (chemokine C-X-C motif ligand) [80]. These events led to
reduced invasion and metastasis formation [76]. Overexpression of
miR-9was observed in ovarian cancer cells (SKOV3) after treatment
with curcumin leading to enhanced cytotoxicity [81]. A curcumin
diet given to mice suffering from B78H1 murine melanoma
revealed distinct tumor regression and a huge overexpression of
the murine miRNA mmu-miR-205-5p (135-fold higher expression)
in the tumors of curcumin-fed mice [82]. The miRNA miR-205-5p
reversed EMT and was downregulated in metastatic melanomas
[83,84]. Curcumin blocked pancreatic cancer cell growth and in-
vasion via induction of miR-7 expression associated with sup-
pression of SET8 expression [85]. In NSCLC cells, curcumin-induced
apoptosis was correlated with the curcumin-mediated upregula-
tion of the tumor suppressors miR-192-5p and miR-215 in a p53-
dependent way leading to down-regulation of XIAP (X-linked in-
hibitor of apoptosis) [86]. A major drawback of curcumin is its low
bioavailability and aqueous solubility, thus, dendrosomal curcumin
formulations were prepared which exhibited improved propertiesPlease cite this article in press as: B. Biersack, Current state of phenolic and
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miR-145 in glioblastoma cells (U87MG) leading to tumor cell
growth inhibition via miR-145-mediated suppression of genes
involved in the formation of cancer stemness properties such as
Nanog, OCT4A (octamer binding protein 4), OCT4B1, and SOX-2
(SRY-box 2) [87]. Dendrosomal curcumin also induced miR-29a
and miR-185 expression in hepatocellular carcinoma (HCC) cells
associated with suppression of the DNA-methylases DNMT1,
DNMT3A and DNMT3b leading to hypomethylation of the MEG3
promoter and increased expression of the tumor suppressing long
non-coding RNA MEG3 [88].
Curcumin reduced the expression of the oncogenic miR-21 in
colon cancer cells (RKO, HCT-116) leading to reduced tumor growth
and metastasis formation by enhanced expression of the miR-21
target PDCD4 (programmed cell death protein 4) [89]. In addition,
curcumin downregulated miR-17-5p, miR-20a, and miR-27a (tar-
geting SP repressors, zinc ﬁnger and BTB-domain proteins such as
ZBTB4/10) in colon cancer cells (RKO, SW480) leading to increased
growth inhibition [90]. MiR-21 was suppressed in A549 NSCLC cells
after treatment with curcumin as well, followed by activation of the
miR-21 target PTEN (phosphatase and tensin homolog) [91]. In
human esophageal cancer cells (TE-7), curcumin induced apoptosis
and cell cycle arrest via suppression of miR-21 and miR-34a, while
the tumor suppressor let-7 was induced by curcumin in these
cancer cells [92]. In addition, curcumin successfully inhibited lung
cancer cell proliferation (both A549 wt and A549/DDP multidrug
resistant cells) and induced apoptosis by downregulation of onco-
genic miR-186* which targets caspase-10 [93,94]. Interestingly,
there's conﬂicting data about the role of miR-200 concerning cur-
cumin treatment. In hepatoma cells (HepG2, HepJ5), over-
expression of miR-200a and miR-200b led to enhanced curcumin
resistance via increased anti-apoptotic Bcl-2 levels and decreased
pro-apoptotic Bad and Bax levels [95]. In contrast to that,
gemcitabine-resistant pancreas cancer cells (MiaPaCa-E, MiaPaCa-
M) showed decreased levels of miR-200b/c while after treatment
with curcumin the levels of miR-200b and miR-200c were
increased in these cells [96]. Modulation of miR-200c expression
(upregulation) also played a role for the curcumin-induced sensi-
tization of colon cancer cells to the approved anticancer drug 5-
ﬂuorouracil (5FU) [97]. In prostate cancer cells (PC3), curcumin
suppressed oncogenic miR-208 in a dose-dependent way, and,
thus, induced the expression of the cell cycle inhibitor andmiR-208
target CDKN1A leading to prostate tumor cell growth inhibition
[98].
Due to the impressive biological activities of curcumin, the
preparation of curcumin derivatives (curcuminoids) with improved
properties has become a valuable strategy to obtain sound anti-
cancer drugs. In particular, ﬂuoro-derivatives of curcumin have
shown improved anticancer activity when compared with their
parent drug curcumin. A remarkable semisynthetic curcuminoid is
CDF, the Knoevenagel condensation product of curcumin and 3,4-
diﬂuorobenzaldehyde (Fig. 1) [99]. CDF exhibited much higher
anticancer activity than curcumin and accumulated in pancreasterpenoidal dietary factors and natural products as non-coding RNA/
n, Non-coding RNA Research (2016), http://dx.doi.org/10.1016/
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diseases [96,98,100]. CDF was able to re-sensitize drug-resistant
pancreatic cancer cells to gemcitabine and enhanced the expres-
sion of tumor suppressor miRNAs (miR-200) while it reduced the
levels of oncogenic miR-21 leading to PTEN upregulation [96,101].
Under hypoxic conditions, prostate cancer cells upregulate miR-21,
however, after treatment with CDF miR-21 expression and tumor
growth was efﬁciently reduced [102]. The hypoxia-mediated
aggressiveness of pancreas cancer cells was also related to
increased expression of miR-21 and miR-210, and treatment with
CDF signiﬁcantly reduced the expression of miR-21 and miR-210
in vitro and in vivo [103]. In addition, CDF reduced miR-21 levels
and restored PTEN expression in colon cancer cells, while expres-
sion of the tumor suppressor miR-34 was induced by CDF in colon
cancer [104,105]. CDF was also able to modulate miRNAs targeting
matrix metalloproteinases (MMPs) which play a crucial role for the
invasion competence of cancers. MiR-874 was upregulated by CDF
in non-small cell lung cancer cells which led to MMP-2 inhibition
[106]. Oncogenic miR-221 was downregulated by CDF in pancreas
cancer cells as well, and CDF inhibited proliferation and migration
of pancreas cancer cells by upregulation of p27, p57, PTEN, and
PUMA (p53 upregulated modulator of apoptosis) [107]. In addition,
CDF upregulated let-7 and miR-101 which suppressed the histone
methyltransferase EZH2 associated with reduced survival, invasion
and cancer stem cell function in pancreatic cancer [108]. The tumor
suppressor miR-143 was likewise induced by CDF in pancreatic
cancer cells as well as the tumor suppressor miR-146a leading to
suppressed EGFR (epidermal growth factor receptor) signaling and
inhibition of pancreatic tumor growth [109,110].
Another interesting synthetic curcuminoid is EF24 [3,5-bis(2-
ﬂuorobenzylidene)piperidin-4-one] which is easily prepared by
condensation of piperidin-4-one with two equivalents of 2-
ﬂuorobenzaldehyde (Fig. 1) [111]. EF24 exhibited distinctly stron-
ger growth inhibition and anti-angiogenic activity than curcumin
[111,112]. Hence, it is not surprising that EF24 efﬁciently suppressed
oncogenic miR-21 in prostate cancer (DU145) and melanoma (B16)
cells and upregulated the miR-21 targets PTEN and PDCD4 [112]. A
recent study of EF24 in melanoma cells disclosed signiﬁcant effects
on miR-33b expression, and suppression of EMT (¼suppression of
metastasis formation) as well as HMGA2 (high-mobility group AT-
hook 2) inhibition were observed after treatment with EF24 asso-
ciated with upregulation of miR-33b [113]. The miRNAs (both tu-
mor suppressor and oncogenic ones) regulated by curcumin and its
derivatives are presented in Table 2.3.1.2. Garcinol
The phenolic natural product garcinol was isolated from the
kokum tree (Garcinia indica) that grows in Western India [114].
Aside its application as a spice for Western Indian dishes, kokum is
also applied in Ayurveda medicine for the treatment of infections
and edema [115,116]. Chemically, garcinol (camboginol) is a type B
polycyclic polyprenylated acylphloroglucinol (PPAP) featuring a
benzophenone derivative with ﬁve isoprenyl side chains attachedTable 2
Regulation of non-coding RNAs/microRNAs by curcumin, curcumin derivatives (CDF, EF2
Compound Tumor suppressors (up-regulated)
Curcumin let-7, miR-7, miR-9, miR-15, miR-16, miR-22, miR-29a
miR-181b, miR-185, miR-192-5p, miR-200b/c, miR-20
miR-215, MEG3
CDF miR-34, miR-101, miR-146a, miR-200, miR-874
EF24 miR-33b
Garcinol let-7, miR-128, miR-200b/c, miR-453, miR-720, miR-12
Garcinol þ Gemcitabine miR-453, miR-663, miR-638, miR-720
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from dried kokum plums, however, there's a total synthetic pro-
cedure of garcinol and its close congener isogarcinol available now
as well [118,119]. The chemical structure of garcinol shows some
similarities with curcumin (b-diketone, phenol). Garcinol has
revealed signiﬁcant anticancer activity by targeting NF-kB, 5-
lipoxygenase (5-LOX), and STAT proteins (for a recent review see
ref. [118]). In addition, garcinol is a well-documented HAT inhibitor
(histone acetylase inhibitor) and, thus, plays an important role for
the epigenetic regulation of gene expression including the
expression of oncogenes [120]. Synergistic effects were observed
from combinations of garcinol with gemcitabine in pancreas cancer
cells (including gemcitabine-resistant Panc-1 cells) due to garcinol-
mediated modulation of miRNAs [121]. Garcinol downregulated
oncogenic miR-21 (0.56-fold), miR-494 (0.97-fold), miR-495 (1.14-
fold), and miR-1977 (0.80-fold) when compared with untreated
pancreas cancer cells [121]. The expression of the micro-RNAs miR-
453 (4.69-fold), miR-128 (1.82-fold), miR-1280 (0.46-fold) andmiR-
720 (0.43-fold) was upregulated by garcinol. The combination of
garcinol with gemcitabine led to downregulation of miR-196a
(0.82-fold), miR-495 (1.26-fold), miR-1914 (1.85-fold), miR-605
(2.42-fold), and miR-483-3p (1.06-fold) as well as upregulation of
miR-638 (0.65-fold), miR-720 (0.41-fold), miR-453 (4.78-fold) and
miR-663 (0.92-fold) [121]. Further to this, in breast cancer cells
(MDA-MB-231, BT-549) garcinol reverted the metastasis-related
EMT mechanism to the non-invasive MET (mesenchymal-to-
epithelial transition) mechanism by induction of expression of the
tumor suppressor miRNAs let-7a, let-7e, let-7f, miR-200b, andmiR-
200c both in vitro and in vivo in breast cancer xenograft models
[122]. The microRNAs regulated by garcinol are presented in
Table 2.3.1.3. Flavanoids
The rich natural product class of the ﬂavanoids (phenylchroman
derivatives) comprises numerous bioactive compounds. In partic-
ular, soy isoﬂavones (3-phenylchromon derivatives) such as gen-
istein (Fig. 2) and daidzein have shownpromising anticancer effects
including tumor growth inhibition and inhibition of metastasis
formation by targeting multiple pathways (e.g., NF-kB, Akt, Wnt
signaling, Notch signaling, androgen receptor signaling) [123].
Genistein downregulated the expression of oncogenic miR-21 in
renal cancer cells (A498) followed by induction of p21 and p38
MAPK (mitogen-activated protein kinase) while cyclin E2 was
suppressed by genistein [124]. In addition, numerous other onco-
genic miRNAs are modulated by genistein. In renal cancer cells,
downregulation of oncogenic miR-23b-3p was observed after
treatment with genistein leading to expression of PTEN followed by
suppression of PI3K (phosphatidylinositol-3-kinase), Akt and IL-32
(interleukin-32) [125]. Genistein reduced the levels of oncogenic
miR-1260b in renal cancer cells (786-O, A498) and, thus, inhibited
Wnt signaling via upregulation of the miR-1260b targets sFRP1
(frizzled-related protein 1), Dkk2 (dickkopf 2 homolog) and Smad4
(mothers against decapentaplegic 4) in these cancer cells [126].4), and garcinol.
Oncogenes (down-regulated)
miR-145,
3, miR-205-5p,
miR-17-5p, miR-20a, miR-21, miR-27a, miR-186*, miR-208
miR-21, miR-210, miR-221
miR-21
80 miR-21, miR-494, miR-495, miR-1977
miR-196a, miR-495, miR-605, miR-483-3p, miR-1914
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B. Biersack / Non-coding RNA Research xxx (2016) 1e23 5Genistein performed analogously in prostate cancer cells (DU-145,
PC-3) where suppression of miR-1260b and Wnt signaling was
observed as well [127]. Oncogenic miR-27a was suppressed by
genistein in various tumors including uveal melanoma (C918),
pancreatic, and ovarian cancer (SKOV3) cells followed by induction
of ZBTB10 (zinc-ﬁnger and BTB domain containing 10) and
Sprouty2, the targets of miR-27a [128e130]. MiR-151, which targets
various factors (e.g., N4BP1, CASZ1, SOX17, IL1RAPL1, ARHGDIA),
features another miRNA suppressed by genistein in prostate cancer
cells (PC-3, DU-145) leading to inhibition of migration and invasion
of prostate cancer cells [131]. Further to this, genistein blockedmiR-
221 and miR-222 expression in prostate cancer cells (PC-3) fol-
lowed by overexpression of ARH1 (aplysia ras homolog 1) and cell
growth, invasion and colony formation inhibition [132]. MiR-223
was likewise suppressed by genistein in pancreatic cancer cells
and induction of Fbw7 (F-box and WD-40 domain protein 7)
expression was observed leading to cancer cell growth inhibition
and apoptosis induction [133]. The G2535 mixture of isoﬂavones
(70.54% genistein, 26.34% daidzein, 0.31% glycitein) reduced onco-
genic miR-221 levels in pancreas cancer cells and inhibited prolif-
eration and migration of pancreas cancer cells by induced
expression of p27, p57, PTEN, and PUMA [107]. In highly metastatic
breast cancer cells (MDA-MB-435), genistein suppressed miR-155
expression accompanied by increased expression of various pro-
apoptotic and antiproliferative miR-155 targets (FOXO3, PTEN,
casein kinase, p27) [134].
In contrast to that, the tumor suppressor miRNAs miR-34a, miR-
574-3p and miR-1296 were upregulated in prostate cancer cells
(PC-3, DU-145) after treatment with genistein [135e137]. While
genistein-mediated induction of miR-34a knocked down HOTAIR
(HOX transcript antisense RNA), overexpression of miR-574-3p
suppressed anti-apoptotic Bcl-xL and enhanced caspase-3 and
caspase-9 activity. Further targets of miR-574-3p included RAC1,
EGFR and EP300 (p300 histone acetyl transferase), while miR-1296
blocks MCM2 (minichromosomemaintenance) expressionwhich is
a crucial factor for functional DNA replication. However, a differing
miRNA modulation by the isoﬂavones genistein and daidzein was
observed in three prostate cancer cell lines [138]. Genistein also
upregulated miR-34a in pancreas cancer cells and, thus, induced
apoptosis and tumor cell growth inhibition by inhibition of Notch-1
signaling [139]. In addition, let-7 and miR-200 were upregulated in
pancreatic cancer after treatment with genistein followed by sup-
pression of miR-200 targets such as ZEB1 (zinc ﬁnger E-box-bind-
ing homeobox 1), slug and vimentinwhich are correlated with EMT
[140]. Genistein also induced miR-146a expression associated with
suppression of pancreatic cancer cell invasion via downregulation
of miR-146a targets such as EGFR, MTA-2, IRAK-1, and NF-kB [141].
More recently, genistein exhibited distinct cell growth inhibition of
breast cancer cells (MCF-7) by up-regulation of miR-23b expression
(56.69-fold compared with untreated cells) [142].Please cite this article in press as: B. Biersack, Current state of phenolic and
microRNA modulators for improved cancer therapy and preventio
j.ncrna.2016.07.001Licorice (Glycyrrhiza glabra) is a well known sweetening plant
and has been applied in folk medicine against inﬂammations, and
as an antioxidant, antidote, demulcent and expectorant drug [143].
Extracts of licorice contain signiﬁcant amounts of the isoﬂavan
glabridin (a phytoestrogen, Fig. 2), which has shown anti-
inﬂammatory, neuro- and cardioprotective activities in addition
to distinct anticancer properties (growth inhibition, anti-
angiogenic and anti-metastatic effects) [144e146]. Glabridin sup-
pressed cancer stem cell-like features in hepatocellular carcinoma
models (HepG2, Huh-7, MHCC97H) by upregulation of miR-148a
and suppression of the miR-148a target SMAD2 (small body size
mothers against decapentaplegic) associated with inhibition of
TGF(transforming growth factor)-b/SMAD2 signaling [147]. Similar
results were obtained from breast cancer cells (MDA-MB-231, Hs-
578T) treated with glabridin [148]. In addition, glabridin inhibited
angiogenesis of breast tumors (MDA-MB-231, Hs-578T) by upre-
gulation of miR-520a [149]. The expression of NF-kB was blocked
by upregulated miR-520a in glabridin-treated breast cancer cells
associated with inhibition of NF-kB/IL-6/STAT-3 signaling.
Glyceollins represent further natural isoﬂavonoids biosyntheti-
cally derived from soy isoﬂavones (e.g., daidzein) which exhibited
interesting anticancer properties (Fig. 2) [150]. These anti-
estrogenic compounds efﬁciently stopped estrogen-induced tu-
mor growth of breast and ovarian cancer models (MCF-7 by 53.4%,
BG-1 by 73.1%) and suppressed estrogen-mediated expression of
the progesterone receptor [151]. In letrozole-resistant breast cancer
cells glyceollin I suppressed ZEB1 (zinc-ﬁnger E-box binding ho-
meobox 1) expression leading to reversal of EMT in these resistant
breast cancer cells [152]. In triple-negative breast cancer cells
(MDA-MB-231, MDA-MB-468) a mixture of glyceollin I (68%), II
(21%) and III (11%), isolated from soybean seeds incubated with
Aspergillus sojae, reduced tumorigenesis by modulation of miRNAs.
In particular, tumor suppressor miRNAs (miR181c, miR-181d) as
well as EMT reversing miRNAs (miR-22, miR-29b, miR-29c, miR-
30d, miR-34a, miR-195) were upregulated by glyceollins while
oncogenic miRNAs increasing tumorigenesis (miR-21, miR-193a-
5p), metastasis formation (miR-185, miR-224), migration and in-
vasion (miR-486-5p) and mesenchymal cell maintenance (miR-
542-5p) were downregulated by glyceollins [153]. The expression
of NME1 (non-metastatic cells 1, target of miR-486-5p and miR-
542-5p), was increased while vimentin (target of miR-30d) was
reduced in glyceollins-treated breast cancer cells [153].
In addition to soy isoﬂavones,many naturalﬂavanoid derivatives
exhibited sound biological activities including antioxidant and
anticancer properties. For instance, (-)-epigallocatechin-3-O-gallate
(EGCG, Fig. 3), the main catechin ﬂavanol of the tea plant (Camilla
sinensis), revealed distinct anticancer activities by modulation of
multiple targets [154]. The induction of apoptosis in hepatoma cells
after treatment with EGCG was associated with an upregulation of
the tumor suppressor miR-16 and inhibition of anti-apoptotic Bcl-2
[155]. In addition,miR-210was induced by EGCG in lung cancer cells
leading to cell growth inhibition [156]. However, the same group
disclosed only modest changes of 21 miRNAs after EGCG treatment
and that miR-210 played a minor role in vivo, while other miRNAs
regulating Akt signaling,MAPK signaling and cell cycle control were
of greater importance in lung cancer models in vivo [157]. For
instance, down-regulation of miR-449c-5p (targets: ACSL1, elmod1,
GAS1, ZFHX4), miR-374c-5p (targets: ART3, cnr1, DCN, EFNA5, GAS1,
ELOVL6, rbm24), andmiR-450a-2-3p (targets: cd19, IGFBP5, ZFHX4)
as well as upregulation of miR-144-3p (targets: AMMECR3, Ccne2,
ZCCHC2) and miR-34b-5p (targets: Ccne2, NRN1) was observed
in vivo after EGCG treatment [157]. In melanoma cells, increased
expression of let-7b via activation of 67LR (67-kDa laminin recep-
tor) was observed after treatment with EGCG [158]. In addition,
EGCG inhibited cell growthof osteosarcoma cells via upregulation ofterpenoidal dietary factors and natural products as non-coding RNA/
n, Non-coding RNA Research (2016), http://dx.doi.org/10.1016/
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B. Biersack / Non-coding RNA Research xxx (2016) 1e236miR-1 expression and induced apoptosis in osteosarcoma cells
through induction ofmiR-126 expression [159,160]. OncogenicmiR-
21 and AR (androgen receptor) signaling were suppressed in pros-
tate cancer cells after EGCG treatment while miR-330 was upregu-
lated leading to reduced prostate tumor growth [161]. The
microRNAs miR-30* (which targets NF-kB, peroxisome-proliferator
activated receptor/PPAR signaling, insulin signaling, glycolysis,
gluconeogenesis, oxidative phosphorylation, glutathione, glycer-
olipids, andmitochondria),miR-453,miR-520-e,miR-608, andmiR-
629were downregulated by EGCG in hepatoma cells (HepG2) [162].
Tsang and coworkers showed that 61 miRNAs were modulated by
EGCG in hepatoma cells (HepG2) (e.g., upregulation of let-7c, miR-
16, miR-18, miR-25, miR-92, and suppression of miR-129, miR-196,
miR-200, miR-342, miR-526) [163]. EGCG-mediated suppression of
miR-98-5p in NSCLC cells (A549) sensitized these tumor cells to
cisplatin treatment [164]. The expression of further miRNAs was
either reduced (oncogenic miR-92, miR-93, miR-106b) or increased
(tumor suppressors miR-7-1, miR-34a, miR-99a) by a combination
of EGCG with N-(4-hydroxyphenyl)retinamide in human neuro-
blastoma cells (SH-SY5Y, SK-N-DZ) [165]. Protection from UVB
irradiation was observed in EGCG-treated dermal ﬁbroblasts via
modulation of various miRNAs [166]. Four miRNAs were upregu-
lated (miR-1246, miR-548c-3p, miR-636, miR-933) and 14 miRNAs
were downregulated (miR-1202, miR-1207-5p, miR-1225-5p, miR-
1227, miR-1271, miR-133a, miR-134, miR-181d, miR-212, miR-362-
3p, miR-455-5p, miR-494, miR-513a-5p, miR-660) in EGCG-
treated dermal ﬁbroblasts [166]. By the way, EGCG was shown to
interact and to bind directly to certain miRNAs (miR-33a, miR-122)
in liver cells and themiRNA binding ability of EGCGwas determined
by 1H NMR spectroscopy [167].
The screening of a series of ﬂavonoids revealed the outstanding
activity of 3,6-dihydroxyﬂavone (3,6-DHF, Fig. 3) against breast
cancer cells [168]. In addition, 3,6-DHF exhibited distinct chemo-
preventive effects in 1-methyl-1-nitrosourea treated breast can-
cer cells by upregulation of miR-34a and downregulation of miR-21
[169]. More recently, the same group disclosed an epigenetic
mechanism for the modulation of miR-34a and miR-21 by 3,6-DHF
in breast cancer cells [170]. Inhibition of the methyltransferase
DNMT1 by 3,6-DHF (probably by binding to the cytosine pocket of
the enzyme) blocked the hypermethylation of the miR-34a pro-
moter which led to enhanced miR-34a expression [170]. Concern-
ing miR-21, 3,6-DHF modulated histone modiﬁcation andPlease cite this article in press as: B. Biersack, Current state of phenolic and
microRNA modulators for improved cancer therapy and preventi
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miR-21 suppression and efﬁcient blocking of the PI3K/Akt/mTOR
signaling pathway [170].
Apigenin represents another ﬂavone derivative found in fruits,
herbs, and vegetables, which induced apoptosis both via the
intrinsic and via the extrinsic pathway and suppressed PI3K/Akt
and ERK1/2 signaling pathways in various cancer cells (Fig. 3)
[171,172]. Apigeninwas shown to inhibit tumor growth both in vitro
and in vivo [173,174]. Decreased expression of miR-138 enhanced
the telomerase activity in tumor cells, which is associated with
malignant growth [175]. The transfection with hTERT short hairpin
RNA (a shRNA, which inhibits hTERT, human telomerase reverse
transcriptase) in combination with apigenin treatment increased
the expression of miR-138 in neuroblastoma cells [175]. In addition,
miR-138 led to enhanced anticancer activity of apigenin and caused
increased apoptosis induction and inhibition of tumor cell growth
and colony formation of neuroblastomas (SK-N-DZ, SK-N-BE2) by
apigenin both in vitro and in vivo [175]. Obesity and diabetes are
considered as signiﬁcant risk factors for various cancer diseases
[176]. In particular, miR-103 overexpression is associated with
glucose intolerance and apigenin efﬁciently loweredmiR-103 levels
by impairing the maturation of this miRNA and by inhibition of
ERK-mediated TRBP (trans-activating response RNA-binding pro-
tein) phosphorylation [177]. In this way, the miR-103 suppressing
properties of apigenin may contribute to the prevention of obesity-
and diabetes-induced cancer types.
The consumption of a diet rich in the ﬂavonol quercetin (Fig. 3),
which is found in apples, grapes and onions, was associated with
the modulation of various miRNAs in lung cancer tissues that play a
distinct role for tumorigenesis including miR-146a (upregulation)
and miRNAs of the let-7 and miR-26 family (tumor suppressing let-
7 and miR-26 miRNAs were signiﬁcantly expressed upon quercetin
consumption) [178]. Quercetin-mediated miR-146a expression
which inhibited NF-kB signaling was associated with anti-
inﬂammation and cancerepreventive activity by protection of
colonic myoﬁbroblasts (CCD-18Co) from damage by ROS (reactive
oxygen species) [179]. In addition, overexpression of let-7 by a
combination of quercetin with catechins inhibited K-Ras signaling
in pancreatic cancer cells as well as tumor growth inhibition [180].
In lung cancer cells (A549), quercetin induced miR-16 expression
and decreased expression of the oncoprotein Claudin-2 in this way
[181]. Unlike gemcitabine, quercetin also induced miR-142-3p
expression in pancreatic cancer cells [182]. In hepatoma cells
(HepG2), quercetin increased the levels of the tumor suppressor
miR-34a associated with suppression of SIRT1 deacetylases in a
p53-dependent way [183]. In contrast to that, oncogenic miR-27a
was suppressed in colon cancer cells by quercetin in combination
with resveratrol leading to enhanced apoptosis induction in the
colon cancer cells [184]. However, quercetin reduced hepatic miR-
125b-3p levels leading to enhanced GGH (g-glutamyl hydrolase)
expression which was linked to methotrexate resistance [185].
Baicalin and baicalein are ﬂavones of the plant Scutellaria bai-
calensis Georgi (applied in TCM, Traditional Chinese Medicine) that
exhibited distinct anti-inﬂammatory and anti-metastatic activities
(Fig. 3) [186,187]. Baicalin induced expression of miR-23a and
suppressed miR-378, miR-199a-3p and miR-181b in UVB-treated
mice, all of them miRNAs that probably play a role for DNA repair
mechanisms [188]. In addition, oncogenic miR-294 expression was
reduced by baicalin in embryonic stem cells (ESCs) associated with
suppression of the oncogenes c-jun and c-fos [189]. Baicalein
exhibited anti-inﬂammatory activity by induction of miR-124
expression in neuronal cells (retinal ganglion cells) leading to
suppression of the inﬂammation factor MCP-1 (monocyte chemo-
tactic protein 1), an effect that might contribute to the chemo-
preventive properties of baicalein as well [190].terpenoidal dietary factors and natural products as non-coding RNA/
on, Non-coding RNA Research (2016), http://dx.doi.org/10.1016/
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nent of the fruits of the milk thistle (Silybum marianum) [191].
Recently, it was shown that silibinin suppressed miR-21 and
enhancedmiR-200c expression in erlotinib-resistant NSCLC tumors
associated with a reversal of EMT and a suppression of mesen-
chymal markers (SNAIL, ZEB, N-cadherin) [192]. A list of microRNAs
regulated by ﬂavanoids is given in Table 3.
3.1.4. Stilbenes
The natural stilbene derivative resveratrol (3,40,5-
trihydroxystilbene) occurs in fruits such as grapes, berries, and
plums and its anticancer properties against various cancer diseases
were thoroughly investigated (Fig. 4) [193,194]. In colon cancer
cells, resveratrol suppressed oncogenic miRNAs such as miR-17,
miR-21, miR-25, miR-92a-2, miR-103-1, and miR-103-2, while tu-
mor suppressor miR-663 (targeting TGF-b) was upregulated by
resveratrol [195]. Oncogenic miR-21 was likewise downregulated
by resveratrol in pancreatic cancer cells associated with enhanced
apoptosis induction via suppression of the anti-apoptotic Bcl-2
protein [196]. Similar effects were observed from resveratrol-
treated prostate cancer cells, where miR-21 suppression upregu-
lated the miR-21 targets PDCD4 and maspin, and from gastric
cancer cells treated with resveratrol [197,198]. The oncogenic
miRNA clusters miR-17-92 and miR-106ab were suppressed by
resveratrol in prostate cancer cells leading to PTEN induction [199].
Resveratrol-mediated downregulation of miR-520h blocked
metastasis formation of lung cancer models by inhibition of FOXC2
(forkhead box C2) [200]. The combination of resveratrol and
quercetin reducedmiR-27a levels leading to ZBTB10 expression and
apoptosis induction in HT-29 colon cancer cells [184]. Resveratrol
inhibited proliferation of MCF-7 breast cancer cells by upregulation
of miR-663 and miR-774 leading to EF1A2 (elongation factor 1A2)
inhibition [201]. In addition, decreased cell invasion by induction of
miR-141 and reversal of EMT via miR-200c upregulation (leading to
ZEB1 suppression and E-cadherin upregulation) was observed after
resveratrol treatment [202]. Synergy effects were observed in lung
cancer cells from the combination of resveratrol with miR-200c
[203]. Further to this, resveratrol-mediated up-regulation of the
tumor suppressor miR-34a was associated with increased cell
growth inhibition and apoptosis induction in colon cancer cells
[204]. In addition, the tumor suppressor miR-34c was induced by
resveratrol in colon cancer cells (HT-29, HCT-116) leading to
increased apoptosis and suppression of the miR-34c target KITLG
(also known as stem cell factor SCF) in vitro and in vivo [205]. The
tumor suppressor miR-622 targets K-Ras and was found to be
upregulated by resveratrol in transformed bronchial epithelial cells
(16HBE-T) leading to cell cycle arrest and suppressed colony for-
mation and tumorigenicity [206]. In hormone-sensitive breast tu-
mors resveratrol inhibited DNA-methyltransferase DNMT3b by up-Table 3
Regulation of microRNAs by ﬂavanoids.
Compound Tumor suppressors (up-regulated)
Genistein let-7, miR-23b, miR-34a, miR-146a, miR-200, miR-574-3p, miR-
Glabridin miR-148a, miR-520a
Glyceollins miR-22, miR-29b, miR-29c, miR-30d, miR-34a, miR-181c,
miR-181d, miR-195
EGCG let-7b, let-7c, miR-1, miR-7-1, miR-16, miR-18, miR-25, miR-34a
miR-34b, miR-92, miR-99a, miR-126, miR-144-3p, miR-210, miR
3,6-DHF miR-34a
Apigenin miR-183
Quercetin let-7, miR-16, miR-26, miR-34a, miR-146a, miR-142-3p
Baicalin, Baicalein miR-23a, miR-124 (anti-inﬂammatory)
Silibinin miR-200c
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miRNA expression study in A549 lung cancer cells revealed that
resveratrol suppressed miR-92a-2 and induced miR-299-5p, miR-
194*, miR-338-3p, miR-758, and miR-582-3p which are likely
involved in the regulation of proliferation, apoptosis, cell cycle and
differentiation processes of lung cancer cells [208]. More recently, a
similar study was carried out with triple-negative MDA-MB-231
breast cancer cells and resveratrol strongly upregulated miR-122-
5p (37.6-fold) and signiﬁcantly downregulated miR-542-3p (11-
fold) and miR-200c-3p (8-fold) playing a key role for the anti-
cancer effects of resveratrol in these cancer cells [209]. Like EGCG,
resveratrol was able bind directly to certainmiRNAs (miR-33a, miR-
122) in liver cells and the miRNA binding ability of resveratrol was
determined by 1H NMR spectroscopy [167].
Piceatannol is a close stilbene analog of resveratrol (Fig. 4) and
occurs in many fruits, in particular, in grapes and red wine which
was associated with the so-called “French paradox” together with
resveratrol. Indeed, piceatannol exhibited distinct anticancer
properties via multiple pathways, and it revealed higher inhibition
of COX-1/2 and CSN-associated kinase than resveratrol [210]. In
leukemia cells (U937), Akt/Foxp3-mediated miR-183 expression
was suppressed by piceatannol leading to inhibition of Sp1-
induced metalloprotease ADAM17 expression and suppression of
TNFa-induced NF-kB [211]. The expression of the tumor suppressor
miR-129 was up-regulated by piceatannol in colon cancer cellsOncogenes (down-regulated)
1296 miR-21, miR-23b, miR-27a, miR-151, miR-155, miR-221, miR-222,
miR-223, miR-1260b
e
miR-21, miR-185, miR-193a-5p, miR-224, miR-486-5p, miR-542-5p
,
-330
miR-21, miR-30*, miR-92, miR-93, miR-98-5p, miR-106b, miR-374c-5p,
miR-449c-5p, miR-450a-2-3p, miR-453, miR-520-e, miR-608, miR-629
miR-21
miR-103 (glucose intolerance)
miR-27a, miR-125b-3p
miR-181b, miR-199a-3p, miR-294, miR-378
miR-21
terpenoidal dietary factors and natural products as non-coding RNA/
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B. Biersack / Non-coding RNA Research xxx (2016) 1e238(HCT-116, HT-29) and increased apoptosis was observed in
piceatannol-treated cells via suppression of Bcl-2 (target of miR-
129) [212]. Bone metastasis are difﬁcult to tackle and cause pain-
ful and life-threatening bone damages, however, both resveratrol
and piceatannol were shown to block osteoclastogenesis by down-
regulation of miR-183 via HO-1 (heme oxygenase-1) induction and,
thus, feature suitable tools for the management and prevention of
bone metastasis [213]. A list of miRNAs regulated by natural stil-
benes is given in Table 4.
3.1.5. Anthraquinones, xanthone and anthracene derivatives
Doxorubicin (Adriamycin, Dox) is a natural anthracycline anti-
cancer drug (inhibitor of topoisomerase II, isolated from Strepto-
myces bacteria) widely applied for the treatment of various
advanced cancer diseases includingmetastatic breast cancer (Fig. 4)
[214]. Resistance factors concerning doxorubicin treatment include
the expression of ABC-transporters (increased drug efﬂux),
enhanced drug metabolism, reduced topoisomerase II levels,
altered p53 function, and apoptosis inhibition [214]. Restored miR-
128 expression in breast cancer stem-like cells (bCSCs) enhanced
the activity of doxorubicin and increased apoptosis and DNA
damage in these drug resistant cells [215]. In addition, miR-451
regulated MDR1 (multidrug-resistance-protein 1) gene expression
and played a crucial role for doxorubicin resistance in MCF-7 breast
cancer cells [216]. Transfection of resistant breast cancer cells with
miR-451 re-sensitized these cancer cells to doxorubicin treatment
[216]. In addition, resistant MCF-7/DOX cells revealed down-
regulated let-7 (target: K-Ras), miR-27b (target: CYP1B1), miR-
34a (target: Notch-1, E2F3), miR-127 (target: Bcl-6) and miR-200c
(target: TCF8), while miR-21 (target: PTEN), miR-28 (target:
BRCA1), miR-106a (target: RB1) and miR-206 (target: ERa) were
upregulated in the doxorubicin-resistant MCF-7 cells [216]. Eroles
and coworkers investigated the miRNA proﬁle of doxorubicin-
treated breast cancer cells and differences between MCF-7 cells
and triple-negative breast cancer (TNBC) cells were observed (25
altered miRNAs were speciﬁc to TNBC cells, including miR-21-3p,
miR-222-5p, miR-181a-3p, and miR-92a-1-5p) [217]. In addition,
the miRNA miR-548c-3p mediated doxorubicin-resistance in
resistant MCF-7 cells [217]. Further to this, receptor tyrosine kinase
TrkB and repressor Bmi1 (B-cell-speciﬁc Moloney murine leukemia
virus integration site 1) were identiﬁed as targets of miR-200c that
mediate doxorubicin-resistance in breast cancer cells (BT474) upon
down-regulation of miR-200c [218]. Doxorubicin-resistant MCF-7
breast cancer cells also exhibited reduced miR-125b and mir-193b
expression associated with upregulated anti-apoptotic Mcl1
(myeloid cell leukemia 1) and inhibition of apoptosis [219,220]. In
addition, drug-resistant breast cancer cells showed reduced miR-
205 levels and restored miR-205 expression sensitized these
breast cancer cells to TAC (docetaxol, doxorubicin, cyclophospha-
mide) treatment again via suppression of VEGFA and FGF2 and
increased apoptosis induction [221]. Low levels of miR-218 were
also observed in drug-resistant breast cancer cells, and re-
expression of miR-218 broke the resistance to doxorubicin via in-
hibition of surviving [222]. MiR-450b-3p expression was signiﬁ-
cantly lowered in HER2/HER3-positive breast cancer cells as well as
in patients with poor prognosis, while overexpression of miR-450b-
3p directly inhibited HER3 expression leading to increasedTable 4
Regulation of microRNAs by stilbenes.
Compound Tumor suppressors (up-regulated)
Resveratrol miR-34a/c, miR-122-5p, miR-141, miR-194*, miR-200c, miR-299-5p,
miR-338-3p, miR-582-3p, miR-622, miR-663, miR-758, miR-774
Piceatannol miR-129
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upon genotoxic treatment induced doxorubicin-resistance in met-
astatic triple-negative breast cancers (TNBC) via STAT-3 activation
and inhibition of pro-apoptotic Bax proteins [224]. Interestingly,
the combination of a miR-10b-inhibitor (miR-10b is overexpressed
in metastatic breast cancer) with low dose doxorubicin exhibited
long-lasting remissions of metastatic breast cancer because of
signiﬁcant growth inhibition and apoptosis induction [225].
Another promising strategy to tackle TNBC was observed from
targeted co-delivery of doxorubicin and miR-542-3p via hyaluronic
acid-modiﬁed polyethyleneimine-poly(D,L-lactide-co-glycolide)
(HA-PEI-PLGA) nanoparticles [226]. The restoration of miR-542-3p
in TNBC cells treated with doxorubicin in this way enhanced
apoptosis induction via p53 activation and survivin suppression
[226]. The tumor suppressor miR-101 was downregulated in he-
patocellular carcinoma (HCC) cells, and transfection of HCC cells
with miR-101 sensitized these cells to treatment with doxorubicin
via suppression of anti-apoptotic Mcl-1 [227]. Doxorubicin-
resistant colon cancer cells (HT-29/Dox) exhibited low miR-522
levels and overexpression of miR-522 restored doxorubicin sensi-
tivity via suppression of ABCB5 expression [228]. In addition, the
mTOR-inhibitor sirolimus distinctly increased miR-34b expression
in osteosarcoma cells leading to enhanced doxorubicin activity via
suppressed PAK1 and ABCB1 expression [229]. In contrast to that,
TGF-b1-mediated miR-202 expression blocked apoptosis induction
in osteosarcoma cells and induced doxorubicin-resistance via
downregulation of PDCD4 [230]. In glioblastoma cells (U87, LN229),
the combination of doxorubicin with a miR-21 inhibitor (miR-21i)
revealed increased anticancer effects by up-regulation of E-cad-
herin, RECK (reversion-inducing-cysteine-rich protein with kazal
motifs), PTEN, VHL (Von Hippel-Lindau tumor suppressor), p21 and
of tumor suppressor miRNAs (miR-200a/b, miR-429, miR-181d)
while the tumor suppressor gene silencing DNA methyltransferase
1 (DNMT1)was suppressed by doxorubicin [231]. The application of
a doxorubicin-conjugated miR-221 molecular beacon suppressed
miR-221 expression efﬁciently while increased anticancer efﬁcacy
was observed in treated glioblastoma cells [232]. In diffuse large B-
cell lymphoma (DLBCL) cells, the expression of miR-199a and miR-
497 distinctly sensitized these lymphoma cells to doxorubicin
treatment. In addition, better overall survival was observed in
DLBCL patients with high miR-199a and miR-497 expression [233].
A list of miRNAs involved in doxorubicin-resistance is given in
Table 5.
Emodin (1,3,8-trihydroxy-6-methylanthraquinone) features
another natural anthraquinone derivative which was isolated from
the roots of the Turkish rhubarb Rheum palmatum, a plant applied
in TCM for the treatment of several diseases (Fig. 4) [234]. Emodin
exhibited distinct anticancer activities via inhibition of tyrosine
kinases [235]. Oncogenic miRNAs miR-221 and miR-222 were
suppressed by emodin in leukemia cells (K562) leading to the in-
duction of erythroid differentiation by upregulation of ALAS2
(aminolevulinate synthase) and of the tyrosine kinase c-KIT [235].
The growth inhibitory effects of emodin in lung cancer cells (A549)
was associated with upregulation of miR-211 and miR-429
expression and suppression of their targets SATB2 (special AT-rich
sequence-binding protein 2) and CRKL (Crk-like protein) [236].
The combination of emodin with curcumin revealed synergisticOncogenes (down-regulated)
miR-17, miR-21, miR-25, miR-27a, miR-92a-2, miR-103-1, miR-103-2, miR-183,
miR-200-3p, miR-520h, miR-542-3p, miR-17-92 cluster, miR-106ab cluster
miR-183
terpenoidal dietary factors and natural products as non-coding RNA/
on, Non-coding RNA Research (2016), http://dx.doi.org/10.1016/
Table 5
MicroRNAs involved in doxorubicin-resistance of cancer cells.
Tumor suppressors (down-regulated) Oncogenes (up-regulated)
let-7, miR-27b, miR-34a, miR-34b, miR-101, miR-125b, miR-127, miR-128,
miR-193b, mir-199a, miR-200c, miR-205, miR-218, miR-450b-3p, miR-451,
miR-497, miR-522, miR-542-3p
miR-10b, miR-21, miR-28, miR-106a, miR-181a, miR-202, miR-206, miR-221,
miR-548c-3p
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and invasion via upregulation of miR-34a and suppression of the
miR-34 targets Bcl-2 and Bmi-1 [237]. In addition, emodinwas able
to suppress Wnt4/Dvl-1/b-catenin signaling by induction of miR-
126 expression [238]. Angiogenesis of pancreatic cancer was
blocked by emodin via upregulation of miR-20b and down-
regulation of miR-155 and miR-210 leading to reduced TGF-b levels
and inhibition of the TGF-b/Smad pathway [239].
Mangiferin represents an important bioactive component of the
Mango plant (Mangifera indica) [240]. Chemically, mangiferin fea-
tures a C-glucosidic xanthone (2-C-b-D-glucopyranosyl-1,3,6,7-
tetrahydroxyxanthone, Fig. 4) with potent antioxidant, anti-
inﬂammatory, anti-diabetic, and anticancer activities (e.g., with
activity against breast, colon, lung and prostate cancer as well as
anti-leukemic activity) [240]. Inhibition of NF-kB and PPARg was
observed for mangiferin [240]. In prostate cancer cells (PC-3),
mangiferin stopped cell growth and induced apoptosis via upre-
gulated miR-182 expression associated with suppressed Bcl-2
expression [241]. In addition, apoptosis induction and levels of
the tumor suppressor miR-15b were increased upon mangiferin
treatment in glioma cells (U87) leading to reduced expression of
MMP-9 which suggests an efﬁcient inhibition of metastasis for-
mation by mangiferin as well [242]. The anthracene derivative
mithramycin A (aureoilic acid, plicamycin) was isolated from soil
bacteria and revealed cell differentiation effects in myeloid leuke-
mia [243]. In erythroleukemia cells (K562), mithramycin A induced
leukemia cell differentiation by induction of miR-210 expression
and g-globin expression [244]. A list of microRNAs regulated by
emodin, mangiferin and mithromycin A is shown in Table 6.
3.1.6. Miscellaneous phenols
Ellagitannins represent natural galloyl and caffeoyl esters of
glucose isolated from the parasitic plant Balanophora japonica that
grows on symploco plants in southern China and Japan and which
is applied as antidote and hemostatic agent in TCM (Traditional
Chinese Medicine) [245]. Derivative BJA3121 (1,3-di-O-galloyl-4,6-
hexahydroxydiphenoyl-b-D-glucopyranose) revealed growth
inhibitory effects on hepatoma cells (HepG2) and modulated the
expression of various miRNAs (e.g., upregulation of let-7e), how-
ever, tumor suppressors were also downregulated (let-7a) and
oncomiRs were upregulated (miR-373*) by BJA3121 in these cells
[246]. In contrast to that, HepG2 hepatoma cells treated with its
close analog BJA32515 (1,3,4-tri-O-galloyl-6-O-caffeoyl-b-D-gluco-
pyranose) exhibited increased expression of the tumor suppressors
let-7a and miR-29a while oncogenic miR-373 and miR-197 were
suppressed (Fig. 5) [247]. Pomegranate (Punica granatum L.) is rich
in polyphenolic compounds and pomegranate extracts exhibitedTable 6
Regulation of microRNAs by emodin, mangiferin, and mithramycin A.
Compound Tumor suppressors (up-regulated) Oncogenes
(down-regulated)
Emodin miR-20b, miR-34a, miR-126,
miR-211, miR-429
miR-155, miR-210,
miR-221, miR-222
Mangiferin miR-15b, miR-182 e
Mithramycin A miR-210 e
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j.ncrna.2016.07.001distinct anticancer and anti-inﬂammatory activities. These prop-
erties correlated with the inhibition of NF-kB and further inﬂam-
matory factors in various cancer cells [248]. A pomegranate extract
with signiﬁcant contents of the ellagitannins punicalagin A, puni-
calagin B (Fig. 5), and of the anthocyanins delphinidin-3-glucoside
and cyanidin-3-glucoside was tested against breast cancer cells
(BT-474, MDA-MB-231) [248]. Indeed, the pomegranate extract
reduced miR-27a levels in these breast cancer cells associated with
increased ZBTB10 (¼Sp-repressor) expression and reduced levels of
Sp, VEGF, VEGFR (vascular endothelial growth factor receptor) and
survivin [248]. In addition, pomegranate extract suppressed miR-
155 leading to upregulation of inositol phosphatase SHIP-1 and
inhibition of PI3K/Akt signaling [248]. Pomegranate extract also
suppressed DNA repair and led to double-strand breaks (DSBs)
accompanied by increased apoptosis in MCF-7 breast cancer cells
via upregulation of miR-24 and miR-183 [249]. Pomegranate ex-
tracts likewise inducedmiR-34a expression depending on activated
p53 leading to suppression of c-Myc and CD44 and increased
apoptosis induction in EJ bladder cancer cells [250].
10-Acetoxychavicol acetate (Fig. 5), a phenolic compound iso-
lated from Alpinia conchigera (wild ginger), modulated the
expression of miRNAs in cervix carcinoma cells (Ca Ski, HeLa) [251].
More precisely, the tumor suppressor miRNAs miR-138, miR-210
and miR-744 were upregulated by 10-acetoxychavicol acetate in
combination with cisplatin [251]. In addition, oncogenic miR-23a
was suppressed in head-and-neck squamous cells (HN4) associ-
ated with PTEN upregulation and increased apoptosis induction
after treatment with 10-acetoxychavicol acetate [252].OH
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B. Biersack / Non-coding RNA Research xxx (2016) 1e2310The biphenol magnolol, [4-allyl-2-(5-allyl-2-hydroxyphenyl)
phenol], was isolated from Magnolia obovata which has been
applied in the Japanese folk medicine for the treatment of cough
and gastrointestinal diseases (Fig. 5) [253]. Magnolol exhibited
growth inhibitory and anti-metastatic activity against various
cancer types and suppressed Wnt signaling in colon cancer cells
[253]. In breast cancer cells (MCF-7), the expression of the tumor
suppressor miR-200c was increased after treatment with magnolol
leading to ZEB1 inhibition and E-cadherin upregulation [254].
Honokiol, [2-(4-hydroxy-3-prop-2-enyl-phenyl)-4-prop-2-enyl-
phenol], features a close analog of magnolol which was isolated
from various Magnolia species (M. ofﬁcinalis, M. obovata, M. gran-
diﬂora) of Southeast and East Asia (Fig. 5) [255]. The biphenol
honokiol revealed distinct anti-oxidative, anti-inﬂammatory and
anticancer activities by targeting multiple factors including
signaling pathways of NF-kB, EGFR, STAT-3 and mTOR (mammalian
target of rapamycin) [256]. In breast tumors, honokiol inhibited
tumor growth via increased expression of miR-34a and STAT-3 in-
hibition associated with suppression of the Wnt1-MTA-b-catenin
signaling pathway [257]. Honokiol also inhibited the growth of
bladder tumors by increased expression of the tumor suppressor
miR-143 leading to suppression of EZH2, MMP-9, CD44, and Sox2
[258].
Caffeic acid (3,4-dihydroxycinnamic acid) and its phenethyl
ester CAPE belong to the active constituents of the propolis extract,
a honey bee hive extract, and also occur in various plants (Fig. 5)
[259]. Caffeic acid and CAPE exhibited distinct antioxidant, anti-
inﬂammatory and anticancer properties [260,261]. A signiﬁcant
suppression of angiogenesis was observed after treatment with
caffeic acid and CAPE [259]. In hepatocarcinoma cells (HepG2,
MHCC97H), caffeic acid increased miR-124 levels via DNA-
demethylation associated with suppression of NF-kB/p65, STAT-3,
and IL-6 (interleukin-6) [262]. In addition, caffeic acid suppressed
cancer stem cell-like features by induction of miR-148a leading to
inhibition of the TGF-b/SMAD2 signaling pathway and blocking of
SMAD2 expression by miR-148a that binds to the SMAD2-30UTR
[263]. CAPE downregulated pro-inﬂammatory miRNAs (miR-9,
miR-125b, miR-146a, and miR-155) in neuronal cells exposed to
Alzheimer's disease derived extracellular ﬂuid via inhibition of NF-
kB which might play a role for the anticancer properties of CAPE as
well [264]. Rosmarinic acid (isolated from rosemary, Rosmarinus
ofﬁcinalis) features another caffeate derivative with distinct anti-
oxidant, anti-inﬂammatory and anticancer effects (Fig. 5) [265]. In
gastric cancer cells (MKN45), rosmarinic acid revealed an anti-
Warburg effect, i.e., it suppressed glycolytic biosynthesis of ATP
which is a common feature of many cancer types [266]. Down-
regulation of the microRNAs miR-155, miR-146a and miR-223 was
observed after treatment with rosmarinic acid as well as suppres-
sion of STAT-3, IL-6 and HIF-Ia (hypoxia inducible factor) [266].
Table 7 provides a list of miRNAs modulated by various phenolic
natural compounds.Table 7
Regulation of microRNAs by miscellaneous phenols.
Compound Tumor suppressors
(up-regulated)
Oncogenes
(down-regulated)
BJA32515 let-7a, miR-29a miR-197, miR-373
Pomegranate extract miR-24, miR-183 miR-27a, miR-155
10-Acetoxychavicol
acetate
miR-138, miR-210, miR-744 miR-23a
Magnolol miR-200c e
Honokiol miR-34a, miR-143 e
Caffeic acid, CAPE,
Rosmarinic acid
miR-124, miR-148a miR-9, miR-125b,
miR-146a, miR-155,
miR-223
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etoposide is derived from the natural product podophyllotoxin and
is applied in advanced stages of breast cancer, lung cancer, leuke-
mia and lymphoma diseases (Fig. 5) [267,268]. Dean and coworkers
investigated the inﬂuence of miRNAs on etoposide sensitivity and
etoposide resistance of breast cancer cells (sensitive MCF-7, resis-
tant MCF-7/VP) [269]. A signiﬁcant upregulation of miR-382, miR-
23b and miR-885-5p (>2-fold) and suppression of miR-218, miR-
758 and miR-548d-5p (>2-fold) was observed from etoposide-
resistant MCF-7/VP cells when compared with sensitive MCF-7
cells [269]. MiR-218 was particularly down-regulated (7.79-fold)
in the resistant MCF-7/VP cells. The authors assumed a link be-
tween the modulation of these miRNAs with the signiﬁcant upre-
gulation of ABC transporters such as ABCC1 and ABCC6 in the
resistant MCF-7/VP cells, which remove etoposide from the cancer
cells again [269]. Recently, increased levels of miR-124 upregulated
the CDK (cyclin-dependent kinase) inhibitor p27 leading to G1 ar-
rest and sensitized breast and ovarian cancer tumors to etoposide
treatment [270]. In hepatoma carcinoma, increased miR-23a
expression enhanced the activity of etoposide by suppression of
topoisomerase 1, the target of miR-23a, and miR-23a expression
depended on functional p53 [271]. HepG2 hepatoma cells were
turned into etoposide-resistant cells by upregulation of miR-210
(induced by hypoxia) while upregulation of miR-196b sensitized
hepatoma cells to etoposide via suppression of IGF2BP1 (insulin-
like growth factor 2 RNA binding protein 1) [272]. Expression of
miR-1915-3p in lung cancer cells inhibited etoposide-induced
apoptosis by suppression of DRG2 (developmentally regulated
GTP-binding protein 2) and PBX2 (pre-B cell leukemia homeobox 2)
[273]. In contrast to that, expression of miR-1469 enhanced
apoptosis induction by etoposide in lung cancer cells via suppres-
sion of STAT5A [274]. The induction of miR-153 reduced the anti-
cancer activity of etoposide in HCC cells via upregulation of survivin
and Bcl-2, and inhibition of p21, PTEN and FOXO1 [275]. In addition,
osteosarcoma cells responded to etoposide treatment by activation
of the tumor suppressor miR-34a in a p53-dependent way [276]. A
list of miRNAs involved in etoposide-resistance and esensitivity is
provided in Table 8.3.2. Terpenoids
3.2.1. Triterpenes
Boswellic acids (Fig. 6) represent the major triterpene constit-
uents of the resin of the plant Boswellia serrata and were found to
be potent anti-inﬂammatory agents (5-LOX inhibitors) [277]. In
addition, signiﬁcant anticancer properties were observed for bos-
wellic acids including the complete remission of brain metastases
in a breast cancer patient after consumption of commercially
available Boswellia extract [278]. The most active boswellic acid is
AKBA (3-acetyl-11-keto-b-boswellic acid) which induced apoptosis
and blocked invasion of cancer cells by inhibition of NF-kB and
STAT-3 signaling [279,280]. In colon cancermodels, AKBA enhanced
the expression of the tumor suppressors let-7 and miR-200 both
in vitro and in vivo leading to reduced CDK6 (cyclin-dependent ki-
nase 6) and vimentin levels [281]. In combination with curcumin,
AKBA upregulated the tumor suppressor miR-34a in colon cancerTable 8
MiRNAs involved in etoposide resistance and sensitivity.
Etoposide-resistance Etoposide-sensitivity
miR-23b, miR-153, miR-210, miR-382,
miR-885-5p, miR-1915-3p
miR-23a, miR-34a, miR-124,
miR-196b, miR-218, miR-548d-5p,
miR-758, miR-1469
terpenoidal dietary factors and natural products as non-coding RNA/
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B. Biersack / Non-coding RNA Research xxx (2016) 1e23 11cells, while miR-27a was suppressed by AKBA and curcumin. The
modulation of these miRNAs was also observed from colon cancer
xenografts (HCT-116) upon treatment with AKBA and curcumin
associated with tumor growth inhibition when compared with
untreated tumors [282].
The bioactive triterpene betulinic acid (Fig. 6) occurs in birch
and plane trees and is easily isolated in signiﬁcant amounts from
the fallen bark of plane trees (Platanus acerifolia) [283]. Betulinic
acid has revealed topoisomerase I inhibition and exhibited distinct
and selective anticancer activity in mouse xenografts (ovarian
cancer, melanoma) while it was non-toxic to the organism at doses
up to 500 mg/kg [284,285]. In colon cancer cells (RKO, SW480),
betulinic acid exhibited growth inhibitory and pro-apoptotic effects
via suppression of miR-27a and induction of the Sp repressor
ZBTB10 (miR-27a target) [286]. Similar effects were observed from
estrogen-negative breast cancer cells (MDA-MB-231) after treat-
ment with betulinic acid [287]. Interestingly, the usually oncogenic
miR-21 was upregulated by betulinic acid in hepatoma cells in aPlease cite this article in press as: B. Biersack, Current state of phenolic and
microRNA modulators for improved cancer therapy and preventio
j.ncrna.2016.07.001p53-dependent way and contributed to the pro-apoptotic proper-
ties of betulinic acid by suppression of Sod2 [288]. In this special
case, miR-21 revealed clear tumor suppressor properties upon
activation by betulinic acid. In addition, betulinic acid suppressed
miR-33 and NF-kB in lipopolysaccharide-treated macrophages and
promoted the expression of the ABC-transporter ABCA1 that is
responsible for the transport of cholesterol and phospholipids
[289].
Ursolic acid features another natural triterpene found in
herbal drug plants such as Radix actinidiae and Oldenlandia diffusa
and revealed signiﬁcant anti-inﬂammatory and anti-cancer ac-
tivities (Fig. 6) [290,291]. In U251 glioma cells, ursolic acid
inhibited tumor cell growth via reduced miR-21 expression
associated with increased expression of apoptotic PDCD4 and
caspase-3 activation as well as blocked TGF-b/SMAD signaling
[292].
Aside glabridin isoﬂavans, licorice extracts also contain signiﬁ-
cant amounts of the triterpene glycyrrhetinic acid (enoxolone, up toterpenoidal dietary factors and natural products as non-coding RNA/
n, Non-coding RNA Research (2016), http://dx.doi.org/10.1016/
Paclitaxel
OO OH
O
HO
O
OO
O
O
O
ONH
OH
O
HO
O
OHO
HO
Andrographolide
O
O
O OO
OH
Triptolide
OH
HO
HO2C
Carnosic acid
O
O
O
Parthenolide
O
O
Antrocin
O
Zerumbone
O
O
Thymoquinone
OO
HO
O
O
O
OHO
HO
OH
OH
Paeoniflorin
Fig. 7. Chemical structures of di-, sesqui- and monoterpenes.
B. Biersack / Non-coding RNA Research xxx (2016) 1e231224% in licorice root extracts) which showed strong apoptosis in-
duction in cancer cells (Fig. 6) [293]. Enoxolone blocked tumor cell
invasion via upregulatedmiR-200c expression in breast cancer cells
accompanied by ZEB1 suppression and E-cadherin upregulation
[254]. The semi-synthetic glycyrrhetinic acid derivative CDODA-Me
(methyl 2-cyano-3,11-dioxo-18b-olean-1,12-dien-30-oate, Fig. 6)
inhibited colon cancer growth (RKO, SW480) in vitro and in vivo via
reduction of miR-27a levels associatedwith increased expression of
the Sp repressor ZBTB10 and upregulation of Myt-1 which causes
G2/M arrest by cdc2 phosphorylation [294]. Interestingly, the gap
junction blocker 18a-glycyrrhetinic acid (18-AGA) was able to
inhibit the intercellular transfer of miRNAs efﬁciently [295].
Cucurbitacins represent further triterpenes with amazing bio-
logical properties. Cucurbitacin I (Fig. 6), for instance, inhibited JAK/
STAT-3 signaling accompanied with strong anticancer activity in
mice [296]. CD4þ T cells (cutaneous T-cell lymphoma, Sezary syn-
drome) treatedwith cucurbitacin I showed reduced IL-21-mediated
oncogenic miR-21 expression and, thus, IL-21 promoted miR-21
expression strongly depended on STAT-3 activation [297].
Apoptosis induction in CD4þ T cells by cucurbitacin I was in parts
mediated by miR-21 suppression. Similarly, the IL-21-induced and
STAT-3 dependent expression of miR-155 was downregulated by
cucurbitacin I [298]. In addition, STAT-3 targeting/suppressing
miRNAs such as miR-337-3p revealed synergistic effects in com-
bination with cucurbitacin I in NCI-H1155 lung cancer cells and the
IC50 values of cucurbitacin I were improved in these cells when co-
treated with miR-337-3p (IC50 ¼ 0.37 mM in miR-337-3p co-treated
cells, IC50 ¼ 1.14 mM for cucurbitacin I alone) [299].
Ginsenosides are triterpene saponins with a terpenoid steroidal
nucleus connected to a sugar fragment and were isolated from the
ginseng plant that is widely applied as a herbal drug both in East
Asia and in the West [300]. In glioma cells (U251), ginsenoside Rh2
(Fig. 6) induced miR-128 expression and suppressed miR-21
associated with tumor cell growth inhibition and apoptosis in-
duction in these tumor cells [301]. The Rh2-mediated modulation
of microRNA expression of A549 non-small cell lung cancer cells
was determined and miR-148a was distinctly upregulated (9.59-
fold) by Rh2 in these lung cancer cells [302]. MiR-148a expres-
sion revealed signiﬁcant antitumor effects in various cancer
models and, thus, likely contributes to the anticancer effects of Rh2
as well. In addition, oncogenic miR-21, miR-23b, miR-27b, miR-100,
miR-221 (4-9-fold) and miR-424 (12.4-fold) were downregulated
by Rh2 in A549 lung cancer cells [302]. Ginsenoside Rg3 features
another triterpene saponin derivative of red ginseng that efﬁ-
ciently blocked angiogenesis via upregulation of miR-520h leading
to suppression of the ephrin receptors EphB2 and EphB3 (Fig. 6)
[303]. A list of microRNAs regulated by triterpenes is presented in
Table 9.3.2.2. Diterpenes, sesquiterpenes and monoterpenes
Paclitaxel (taxol) is a clinically approved natural diterpene
anticancer drug initially isolated from the Paciﬁc yew (Taxus bre-
vifolia) that induces cell death via microtubule stabilization (Fig. 7)
[304,305]. The formation of paclitaxel resistance is a seriousTable 9
Interaction with and regulation of microRNAs by triterpenes.
Compound Tumor suppressors (up-regulate
Boswellic acids (AKBA) let-7, miR-34a, miR-200
Betulinic acid miR-21(!)
Ursolic acid e
Glycyrrhetinic acid derivatives miR-200c
Cucurbitacin I (synergism with miR-337-3p)
Ginsenosides (Rh2, Rg3) miR-148a, miR-520h
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resistance to paclitaxel. Forty human cancer cell lines were inves-
tigated for miRNAs involved in in vitro sensitivity to paclitaxel and
two miRNAs, miR-30a-5p and miR-367, were identiﬁed to play a
crucial role [306]. While expression of miR-367 increased paclitaxel
activity, expression of miR-30a-5p reduced paclitaxel efﬁcacy in
cancer cells [306]. In ovarian cancer cells (A2780), paclitaxel
sensitivity was associated with miR-149 downregulation and
enhanced MyD88 expression [307]. In addition, increased expres-
sion of miR-320a, miR-22 and miR-129-5p as well as reduced
expression of miR-9, miR-155 and miR-640 were observed in
ovarian cancer cells resistant to paclitaxel (ST30 cells) [308]. The
miR-9 target RAB34 (a GTPase) might play a role for the observed
paclitaxel-resistance [308]. MiR-433 features another oncogenic
miRNA that is upregulated in paclitaxel-resistant ovarian cancer
cells (A2780) leading to suppression of CDK6 and to cellular
senescence [309]. In addition, expression of miR-130b and of miR-
197 contributed to paclitaxel-resistance in ovarian cancer cells
[310,311]. Paclitaxel-resistant epithelial ovarian cancer revealed
high levels of miR-1307, which was associated with drug resistance
[312]. Mimics of miR-200c and miR-141 sensitized drug-resistant
ovarian carcinoma cells (MES-OV) to paclitaxel treatment via
reversal of EMT (induction of E-cadherin, suppression of vimentin)
[313]. Further to this, expression of miR-873 downregulated the
drug efﬂux transporter ABCB1 and increased the anticancer activity
of paclitaxel in ovarian cancer cells [314]. Distinctly increased
expression of miR-622 and miR-663 featured bad prognosis factors
for patients suffering from taxol-resistant ovarian cancer, while
expression of miR-647 indicated good prognosis for taxol-sensitive
ovarian cancer patients [315]. The expression of miR-125ad) Oncogenes (down-regulated)
miR-27a
miR-27a, miR-33
miR-21
miR-27a
miR-21, miR-155
miR-21, miR-23b, miR-27b, miR-100, miR-221, miR-424
terpenoidal dietary factors and natural products as non-coding RNA/
on, Non-coding RNA Research (2016), http://dx.doi.org/10.1016/
Table 10
MiRNAs involved in paclitaxel resistance and sensitivity.
Paclitaxel-resistance Paclitaxel-sensitivity
miR-19a, miR-21, miR-22, miR-30a-5p, miR-129-5p, miR-130b, miR-149, miR-153,
miR-133a/b, miR-197, miR-205, miR-320a, miR-361-3p, miR-375, miR-433, miR-490,
miR-520h, miR-622, miR-663, miR-1307
let-7b, miR-9, miR-10b, miR-16, miR-17, miR-17-5p, miR-34a, miR-122,
miR-125a, miR-130a, miR-134, miR-141, miR-155, miR-200c, miR-218,
miR-367, miR-494, miR-497, miR-647, miR-873, miR-877, miR-1204
B. Biersack / Non-coding RNA Research xxx (2016) 1e23 13sensitized cervical cancer to paclitaxel treatment via suppression of
STAT3, while miR-375 expression reduced paclitaxel sensitivity by
induction of EMT processes [316,317]. MiR-490-3p features another
oncomir in ovarian cancer cells that mediates paclitaxel resistance
via upregulation of Pgp and GST-p [318]. Induction of miR-134 in
endometrial cancer cells (ECS) promoted paclitaxel activity by in-
hibition of POGLUT1 (protein O-glucosyltransferase 1) and Notch
signaling [319]. Reduced levels of miR-218 were found in taxol-
resistant breast cancer cells, and re-expression of miR-218 broke
the resistance to taxol via inhibition of survivin [222]. Upregulation
of the RNA-processing enzyme Dicer induced the expression of
miR-494 and increased the activity of paclitaxel in breast cancer via
suppression of AXL kinase [320]. In contrast to that, expression of
miR-520h promoted paclitaxel-resistance in breast cancer cells
associated with inhibition of DAPK2 (death-associated protein ki-
nase 2) expression [321]. Breast cancer cells expressing miR-621
inhibited FBXO11 expression and activated p53 leading to
enhanced sensitivity to paclitaxel treatment [322]. Patients
suffering from luminal A subtype breast cancer resistant to neo-
adjuvant chemotherapy (NAC, paclitaxel plus epirubicin) exhibited
distinctly stronger expression of miR-19a and miR-205 than drug-
sensitive patients [323]. In addition, breast cancer patients who
received NAC exhibited increased expression of miR-34a and miR-
122, which may contribute to the anticancer activity of paclitaxel
and epirubicn [324]. In paclitaxel-resistant lung cancer cells, miR-
16 and miR-17 were downregulated leading to induction of anti-
apoptotic Bcl-2, and expression of miR-16 and miR-17 enhanced
apoptosis induction by paclitaxel via suppression of Bcl-2 as well as
autophagy inhibition via Beclin-1 downregulation [325]. In addi-
tion, miR-17-5p was downregulated in paclitaxel-resistant lung
cancer cells accompanied by Beclin-1 upregulation [326]. A pH-
dependent liposomal formulation of a combination of antagomir-
10b and paclitaxel released antagomir-10b and paclitaxel at lower
pH values and inhibited lung metastasis formation and tumor
growth inhibition of 4T1 breast tumors by suppression of miR-10b
[327]. Another formulation of a special copolymer including poly-
ethylene glycol 5000, vitamin E and diethylenetriamine (PEG5K-
VE4-DET20) was loaded with a let-7b mimic and paclitaxel and
exhibited increased anticancer activity (increased growth inhibi-
tion and apoptosis induction as well as reduced invasiveness) in
KRAS-mutant lung cancer (A549) both in vitro and in vivo [328]. In
gastric cancer cells (SGC7901), miR-21 expression mediated
paclitaxel-resistance and inhibition of miR-21 restored paclitaxel
activity in these cancer cells via suppression of the drug efﬂux
transporter P-gp [329]. Patients suffering from metastatic and
recurrent gastric cancer with low levels of miR-1 and miR-27a
revealed better responses to a combination of paclitaxel and ﬂuo-
ropyrimidine than patients with high expression of miR-1 andmiR-
27a [330]. Downregulation of miR-203 was observed in paclitaxel-
resistant colon cancer cells, and induced expression of miR-203
suppressed SIK2 (salt-inducible kinase 2) expression leading to
sensitization to paclitaxel [331]. In HCT-116 colon cancer cells,
upregulation of miR-497 suppressed the oncogene Smurf1 leading
to increased paclitaxel activity [332]. In paclitaxel-resistant pros-
tate cancer cells, miR-130a was downregulated and re-expression
of miR-130a promoted the activity of paclitaxel via apoptosis acti-
vation [333]. Paclitaxel-resistant nasopharyngeal carcinoma (NPC)Please cite this article in press as: B. Biersack, Current state of phenolic and
microRNA modulators for improved cancer therapy and preventio
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miR-1204, and restored miR-634 and miR-1204 expression sensi-
tized NPC cells to paclitaxel treatment in vitro and in vivo again
[334,335]. The expression of miR-153 diminished the anticancer
activity of paclitaxel in HCC cells via upregulation of survivin and
Bcl-2, and inhibition of p21, PTEN and FOXO1 [275]. In addition,
treatment of HCC cells with paclitaxel upregulated the tumor
suppressor miR-877 and induced tumor cell growth inhibition by
suppression of FOXM1 [336]. Inhibition of miR-133a/b and miR-
361-3p induced cell cycle arrest (S phase arrest) and apoptosis
(activation of caspase-3/7) and enhanced distinctly the anti-
proliferative effects of paclitaxel in NSCLC cells (H1993) [337]. A
list of miRNAs involved in paclitaxel-resistance and esensitivity is
provided in Table 10.
The labdane diterpene andrographolide of Andrographis pan-
iculata has revealed chemopreventive effects and protected A549
alveolar epithelial cells from damages induced by cigarette smoke
(Fig. 7) [338]. In these cells, andrographolide increased the
expression of miR-218 accompanied by reduced NF-kB signaling
(reduced IkB-a phosphorylation and lowered p65 accumulation in
the nucleus) leading to reduced inﬂammation [338]. In addition,
andrographolide increased the expression of miR-23a-5p, miR-
30b-5p, miR-106b-5p and miR-222-3p in hepatoma cells leading to
hepatoma growth inhibition [339].
Triptolide features an anticancer active diterpene triepoxide
lactone of the Chinese plant Tripterygium wilfordii (thunder god
vine, applied in TCM) and suppressed the heat shock protein Hsp70
in cancer cells associated with cancer cell growth inhibition (Fig. 7)
[182]. Unlike the approved anti-pancreatic cancer drug gemcita-
bine, triptolide also induced miR-142-3p expression (a miRNA
repressor of Hsp70) in pancreatic cancer cells, while minnelide, the
water-soluble triptolide prodrug, increased miR-142-3p expression
in vivo in a pancreatic cancer xenograft model [182]. Further to this,
triptolide augmented the MDM2-suppressing effects of miR-339-
5p both in MCF-7 breast cancer and in HCT-116 colon cancer cell
lines after induction of the p53 inhibitor MDM2 by the approved
anticancer drug 5-FU [340].
Aside rosmarinic acid, rosemary (Rosmarinus ofﬁcinalis L.) ex-
tracts also contain bioactive diterpenes such as carnosol and car-
nosic acid (Fig. 7) [341]. Both carnosol and carnosic acid showed
antitumor activity against pancreatic and colon cancer both in vitro
and in vivo by suppression of miR-15b and induction of glycosyl-
transferase GCNT3 [342]. In addition, carnosic acid in combination
with 1,25-dihydroxyvitamin D3 reduced miR-181a levels in leuke-
mia cells (HL-60, U937) leading to cell cycle arrest and cell differ-
entiation [343].
Sesquiterpenes have shown potent anticancer activities, for
instance, the fungal compound class of illudins exhibited strong
tumor growth inhibitory activity via unique DNA binding proper-
ties [344]. The sesquiterpene lactone parthenolide (Fig. 7) isolated
from feverfew (Tanacetum parthenium) has also shown distinct
anticancer activity in various cancer cell lines and parthenolide
showed NF-kB inhibition and DNA hypomethylation via DNMT1
suppression [345]. Thus, miRNA modulation by parthenolide was
assumed and in acute myelogenous leukemia cells (MOLM-13),
parthenolide indeed increased the expression of the known tumor
suppressors miR-15a and miR-16 [346].terpenoidal dietary factors and natural products as non-coding RNA/
n, Non-coding RNA Research (2016), http://dx.doi.org/10.1016/
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Fig. 8. Chemical structures of lipophilic vitamins and of their derivatives.
B. Biersack / Non-coding RNA Research xxx (2016) 1e2314The medicinal fungus Antrodia camphorata contains the
sesquiterpene lactone antrocin (Fig. 7) that has revealed strong
anticancer activity in triple-negative breast cancer cells (MDA-MB-
231) [347]. In addition, antrocin revealed growth inhibition and
apoptosis induction in lung cancer cells (H441, geﬁtinib-resistant
H1975) via increased let-7c expression associated with STAT3 in-
hibition [348]. Another Southeast Asian ginger sesquiterpene, zer-
umbone (Fig. 7), induced apoptosis in Panc-1 pancreatic cancer
cells via increased expression of miR-34 accompanied by p53 and
p21 activation [349].
Monoterpenes such as menthol have shown antitumor activity
against various cancer cells, and monoterpene conjugates even
overcame cisplatin-resistance [350e352]. Thymoquinone (TQ,
Fig. 7) represents the active monoterpene component of the oil of
black seeds (Nigella sativa), a frequently applied plant (kalonji) in
traditional Indian medicine (Ayurveda, Unani), and exhibited sig-
niﬁcant antineoplastic effects [353]. Among others, polo-like ki-
nases (Plk) were identiﬁed as tumor targets for thymoquinone
[354]. Recently, a PEGylated thymoquinone nanoparticle
(PEG4000-TQ-Np, PEG ¼ polyethylene glycol) with improved
aqueous solubility and tumor selectivity was prepared and inves-
tigated for its anticancer properties in breast cancer cells [355]. This
nanoparticle exhibited increased breast tumor cell killing and anti-
migratory activity by upregulation of miR-34a and downregulation
of its target Rac1 (a Rac GTPase) leading to actin depolymerisation
[355].
Paeoniﬂorin represents a major monoterpene glucoside of the
medicinal plant Paeonia lactiﬂora Pall. and blocked tumor cell in-
vasion and metastasis (Fig. 7) [356]. Paeoniﬂorin also inhibited
glioma cell growth (U87) and induced apoptosis in glioma cells via
upregulation of miR-16 and suppressed MMP9 expression [357]. In
addition, paeoniﬂorin showed protective effects on doxorubicin-
treated cardiomyocetes via suppressed miR-1 expression and in-
hibition of doxorubicin-induced apoptosis in cardiomyocetes [358].
A list of microRNAs regulated by di-, sesqui- and monoterpenes is
presented in Table 11.3.2.3. Terpenoidal vitamins A, D, and E
Retinoic acid (RA, vitamin A, Fig. 8) is an essential natural
diterpene for the regulation of cell growth and differentiation
through binding to retinoic acid receptors (RARs) and revealed
anticancer effects in various cancer models including breast, pros-
tate, lung, liver, and pancreatic cancer [359]. In acute promyelocytic
leukemia cells, retinoic acid induced the expression of several
miRNAs such as let-7a-3, let-7c, miR-15a, miR-15b, miR-16-1, miR-
107, miR-186, miR-215, miR-223, and miR-342, while ﬁve miRNAs
(miR-17, miR-25, miR-93, miR-193, miR-181b) were suppressed
after treatment with retinoic acid [360,361]. Though the inhibition
of breast cancer cell growth by retinoic acid was counteracted byTable 11
MicroRNAs regulated or inﬂuenced by di-, sesqui- and monoterpenes.
Compound Tumor suppressors
(up-regulated)
Oncogenes
(down-regulated)
Andrographolide miR-23a-5p, miR-30b-5p,
miR-106b-5p, miR-218,
miR-222-3p
e
Triptolide miR-142-3p, miR-339-5p
(synergism)
e
Carnosic acid e miR-15b, miR-181a
Parthenolide miR-15a, miR-16 e
Antrocin let-7c e
Zerumbone miR-34 e
PEG-Thymoquinone miR-34a e
Paeoniﬂorin miR-16 e
Please cite this article in press as: B. Biersack, Current state of phenolic and
microRNA modulators for improved cancer therapy and preventi
j.ncrna.2016.07.001RA-induced expression of miR-21, RA-induced expression of miR-
21 also inhibited the motility of estrogen-receptor(ER)-positive
breast cancer cells (MCF-7) and suggested a beneﬁcial effect con-
cerning the anti-metastatic properties of retinoic acid via sup-
pression of maspin [362]. In neuroblastoma cells (SH-SY5Y),
retinoic acid induced differentiation via upregulation of miR-10a
and miR-10b [363]. The SR-family splicing factor SFRS1 was iden-
tiﬁed as an important target of miR-10a and miR-10b upon treat-
ment with retinoic acid. In addition, miR-10a and miR-10b
mediated the anti-migratory and anti-metastatic activity of retinoic
acid in these neuroblastoma cells [363]. In addition, retinoic acid
induced neuroblastoma differentiation by upregulation of miR-9
and miR-103 associated with suppression of the expression of the
differentiation inhibitor ID2 (inhibitor of DNA binding-2) [364]. In
breast cancer, levels both of RARb and of the tumor suppressormiR-
10a were reduced and a positive correlation between miR-10a and
RARb was assumed [365]. Indeed, retinoic acid was able to upre-
gulate miR-10a expression (2-fold) in breast cancer cells either
alone (in SK-BR-3 cells) or in combination with thyroid hormone
receptor/THRa-binding L-thyroxine (in T47D cells) [365]. Retinoic
acid also downregulated c-Myc and miR-130a in cancer cells
leading to increased HOXA5 expression and cell death [366]. The
differentiation of embryonic stem cells (ESCs) was induced by
retinoic acid via suppression of miR-200b and miR-200c and of
pluripotent genes such as Oct4 and Nanog [367]. Hence, in this
special case the tumor suppressors miR-200b and miR-200c act as
promoters of stem-cell properties such as pluripotency and
immortality which can be suppressed by retinoic acid. In addition,
the tumor suppressor miR-663 was upregulated by retinoic acid in
leukemia cells (HL-60) leading to leukemia cell differentiation
[368]. By the way, miR-10a was downregulated in these HL-60
leukemia cells after treatment with retinoic acid [368]. In glio-
blastoma cells, retinoic acid enhanced the anticancer effects of
transfected miR-124-3p by formation of gap junctions and simpli-
ﬁed intercellular transfer of miR-142-3p [369]. In addition, retinoic
acid induced glioma cell death by induction of miR-302b leading to
suppression of the transcriptional glioma growth regulator E2F3
[370]. Retinoids are derived from carotenoids and lycopene (Fig. 8)
features an interesting carotenoid antioxidant from tomatoes that
inhibited tumor growth [371]. In prostate cancer (PC3 cells), lyco-
pene revealed growth inhibition and apoptosis induction via
upregulation of let-7f-1 associated with suppression of Akt2 (let-
7f-1 target) [372].terpenoidal dietary factors and natural products as non-coding RNA/
on, Non-coding RNA Research (2016), http://dx.doi.org/10.1016/
Table 12
MicroRNAs regulated by lipophilic vitamins and vitamin derivatives.
Compound Tumor suppressors (up-regulated) Oncogenes (down-regulated)
Retinoic acid let-7a-3, let-7c, miR-9, miR-10a, miR-10b, miR-15a, miR-15b,
miR-16-1, miR-21(!), miR-103, miR-107, miR-124-3p, miR-186,
miR-215, miR-223, miR-302b, miR-342, miR-663
miR-17, miR-25, miR-93, miR-130a, miR-181b, miR-193,
miR-200b(!), miR-200c(!)
Lycopene let-7f-1 e
1,25-Dihydroxy-vitamin D3 let-7a-2, miR-15a, miR-20b, miR-22, miR-100, miR-125b
(prostate cancer), miR-181C, miR-296-3p, miR-498, miR-627
miR-17e92 cluster, miR-181a, miR-181b
Tocopherol, delta-Tocotrienol miR-34a, miR-122a, miR-125b e
Antroquinonol miR-15a, miR-18a, miR-2861, miR-302b, miR-382, miR-487a, miR-760 miR-10a (lung cancer), miR-135a, miR-299-3p,
miR-3126-5p, miR-3153, miR-411, miR-4321, miR-486-5p,
miR-505, miR-598, miR-601, miR-939
B. Biersack / Non-coding RNA Research xxx (2016) 1e23 15Vitamin D and its active metabolite 1,25-dihydroxyvitamin D3
(1,25-D, Fig. 8) are essential natural 9,10-seco-steroids that bind to
the vitamin D receptor (VDR) and, thus, modulate various signaling
pathways leading to cell cycle arrest (G0/G1), apoptosis and cell
differentiation [373]. 1,25-D induced miR-22 expression in colon
cancer cells (SW480-ADH, HCT-116) and suppressed target genes
such as NELL2, OGN, HNRPH1, RERE and NFAT5 associated with
anti-proliferative and anti-migratory effects of 1,25-
dihydroxyvitamin D3 [374]. On the other hand, 1,25-D inhibited
AraC-induced apoptosis of acute myeloid leukemia cells by induc-
tion of miR-32 via Bim [375]. 1,25-D increased miR-627 expression
in colon cancer models associated with suppressed JMJD1A (a
histone demethylase) and growth and differentiation factor 15
leading to colon tumor growth inhibition [376]. The tumor sup-
pressors miR-22, miR-296-3p andmiR-498 were induced by 1,25-D
in cervical cancer cells (SiHa) accompanied by increased Dicer
expression [377]. Dicer expressionwas increased by 1,25-D because
of the vitamin D response element in the Dicer promoter [377]. In
addition, the tumor suppressor let-7a-2 was induced by 1,25-D in
lung cancer cells (A549), while the tumor suppressors miR-100 and
miR-125b were upregulated by 1,25-D in prostate cancer cells
[378,379]. However, in MCF-7 breast cancer cells, miR-125b acted
as a repressor for VDR and, thus, induced resistance to 1,25-D via
reduced levels of VDR [380]. In humanmyeloid leukemia cells, 1,25-
D suppressedmiR-181a andmiR-181b leading to cell cycle arrest by
upregulation of p27KIP1 and p21CIP1 [381]. In addition, down-
regulation of the miR-17e92 cluster contributed to 1,25-D anti-
cancer activity in NSCLC cells [382]. 1,25-D also upregulated miR-
15a, miR-20b, and miR-181C in HUVECs (human umbilical vein
endothelial cells) which contributed to the anti-angiogenic activity
of vitamin D [383].
Tocopherol (vitamin E, Fig. 8) is a natural 6-chromanol with an
isoprenoid side-chain that possesses antioxidant properties [384].
Vitamin E deﬁciency led to decreased levels of miR-122a and miR-
125b (i.e., microRNAs involved in lipid metabolism, cancer and
inﬂammation) in the liver of rats [385]. Downregulated miR-122a
and miR-125b were observed from various cancer types and it is
assumed that induction of these miRNAs contributes to the anti-
cancer effects of tocopherol [385]. Tocotrienols are closely related
to tocopherol and exhibited apoptosis induction via inhibition of
signaling pathways such as PI3K/Akt and NF-kB [386]. In non-small
cell lung cancer cells, delta-tocotrienol (Fig. 8) increased the
expression of the tumor suppressor miR-34a leading to inhibition
of Notch-1 signaling [387]. Delta-tocotrienol-induced expression of
miR-34a suppressed the expression of Notch-1 and of its down-
stream factors (Hes-1, Cyclin-D1, Survivin, Bcl-2) associated with
lung tumor cell growth inhibition, apoptosis induction and inhi-
bition of lung cancer cell invasion [387]. Antroquinonol is a struc-
turally related ubiquinone derivative of the camphor tree
mushroom Antrodia camphorata which is applied in TCM for the
treatment of several diseases (Fig. 8) [388]. Antroquinonol inhibitedPlease cite this article in press as: B. Biersack, Current state of phenolic and
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activated protein kinase) activation and mTOR inhibition [389]. In
non-small cell lung cancer cells, antroquinonol revealed anti-
proliferative activity and suppressed the expression of Bcl-2, PI3K
and mTOR proteins [390]. Seven microRNAs (miR-15a, miR-18a,
miR-2861, miR-302b, miR-382, miR-487a, miR-760) were upregu-
lated in A549 lung cancer cells treated with antroquinonol, while
twelve miRNAs were downregulated (miR-10a, miR-135a, miR-
299-3p, miR-3126-5p, miR-3153, miR-411, miR-4321, miR-486-5p,
miR-505, miR-598, miR-601, miR-939) after antroquinonol treat-
ment [390]. A list of microRNAs regulated by terpenoidal vitamins
is presented in Table 12.4. Conclusions
Various natural phenolic and terpenoidal compounds of known
anticancer activity exerted their anticancer activity via regulation of
microRNAs involved in proliferation, cell death and differentiation,
angiogenesis andmetastasis formation. Quite a few of these natural
compounds (e.g., curcumin, boswellic acid, etc.) have shown low
toxicity both in animal studies and in clinical trials and appear to be
suitable additives to conventional cancer therapies. In addition, the
sensitivity and resistance of cancer cells to approved phenolic and
terpenoidal anticancer agents such as doxorubicin, etoposide and
taxol include modiﬁed expression of tumor suppressor and onco-
genic miRNAs. A detailed understanding of the miRNA regulation
by natural phenols and terpenes will provide essential information
for improved therapy regimens including combination therapies
with approved anticancer drugs or other conventional therapies
associated with improved prognoses, reduced side-effects,
increased quality of life of cancer patients, and breach or preven-
tion of drug resistance.References
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